The Combo Test-Plus allows to anticipate the diagnosis,
reducing invasivity, costs and response time and
therefore represents the most advanced screening
method for cervical cancer
1. a first screening is carried out coupling the cytological evaluation of the thin layer cervical cell and the search for the RNA of 14 high risk HPV genotypes (16,18,31,33,35,39,45,51,52,56,58,59,66,68)
2. in case of low dysplasia with or without HPV RNA, a FISH (Fluorescence In Situ Hybridization) of the cervical cells is performed as a reflex test to assess the real nature of the atypical cells.
All in one, in the same specimen, no need to repeat the sampling.